Search results for " Cardiovascular Disease"

showing 10 items of 179 documents

Hipercolesterolemia familiar homocigota: adaptación a España del documento de posición del grupo de consenso sobre hipercolesterolemia familiar de la…

2015

Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening disease characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). The Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) has recently published a clinical guide to diagnose and manage HoFH (Eur Heart J. 2014;35:2146-57). Both the Spanish Society of Atherosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF) consider this European Consensus document of great value and utility. However, there are particularities in our country which advise to ha…

medicine.medical_specialtyEzetimibeHomozygous familial hypercholesterolaemiaDiagnosisMedicinePharmacology (medical)Lipoprotein cholesterolNational healthEzetimibabusiness.industryAtherosclerotic cardiovascular diseaseDiagnósticoAféresisStatinsHipercolesterolemia familiar homocigotaLomitapidaEzetimibeLomitapidePatient managementLDL apheresisFamily medicineEuropean atherosclerosis societylipids (amino acids peptides and proteins)ApheresisCardiology and Cardiovascular MedicinebusinessEstatinasmedicine.drug
researchProduct

Cardiovascular disease in primary sjögren’s syndrome

2018

Background A close relationship between rheumatic diseases and cardiovascular disease (CVD) has been reported, accounting for the higher mortality and morbidity observed in these patients. In the last years, it has been clearly reported that patients affected by primary Sjogren's syndrome (pSS) experienced an increased risk of CVD. Objective This review aimed at investigating CVD, traditional cardiovascular (CV) risk factors and possible targeted therapeutic strategies in pSS patients. Method Available literature concerning CV risk factors in pSS patients has been selected and discussed. Conclusion Disease-related characteristics and traditional CV risk factors contribute to observed athero…

medicine.medical_specialtyFuture studiesEndothelial damageDiseaseType 2 diabetesComorbidity030204 cardiovascular system & hematologySjögren syndrome03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineMedicineHumans030212 general & internal medicinePharmacologybusiness.industryRisk FactorGeneral Medicinemedicine.diseaseAtherosclerosisCardiovascular diseaseCardiovascular riskComorbiditySjögren syndromestomatognathic diseasesSettore MED/16 - ReumatologiaAtherosclerosis; Cardiovascular disease; Cardiovascular risk; Comorbidity; Endothelial damage; Sjögren syndrome; PharmacologyIncreased riskSjogren's SyndromeClose relationshipCardiovascular DiseasesAtherosclerosiSjogren sbusinessHuman
researchProduct

Therapeutical approach to plasma homocysteine and cardiovascular risk reduction

2008

Marcello Ciaccio, Giulia Bivona, Chiara BelliaDepartment of Medical Biotechnologies and Forensic Medicine, Faculty of Medicine, University of Palermo, ItalyAbstract: Homocysteine is a sulfur-containing aminoacid produced during metabolism of methionine. Since 1969 the relationship between altered homocysteine metabolism and both coronary and peripheral atherotrombosis is known; in recent years experimental evidences have shown that elevated plasma levels of homocysteine are associated with an increased risk of atherosclerosis and cardiovascular ischemic events. Several mechanisms by which elevated homocysteine impairs vascular function have been proposed, including impairment of endothelial…

medicine.medical_specialtyHyperhomocysteinemiaHomocysteineReviewRM1-950folatehomocysteine MTHFR cardiovascular disease folate B vitaminchemistry.chemical_compoundcardiovascular diseaseInternal medicineMedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsEndothelial dysfunctionchemistry.chemical_classificationReactive oxygen speciesChemical Health and SafetyMethioninebiologybusiness.industryhomocysteineGeneral MedicineMetabolismmedicine.diseaseB vitaminB vitaminsEndocrinologychemistryMethylenetetrahydrofolate reductaseMTHFRbiology.proteinTherapeutics. PharmacologybusinessSafety ResearchTherapeutics and Clinical Risk Management
researchProduct

Effect of low-dose aspirin on health outcomes: An umbrella review of systematic reviews and meta-analyses.

2020

Aims:\ud \ud This study aimed to use an umbrella review methodology to capture the range of outcomes that were associated with low‐dose aspirin and to systematically assess the credibility of this evidence.\ud \ud Methods:\ud \ud Aspirin is associated with several health outcomes, but the overall benefit/risk balance related to aspirin use is unclear. We searched three major databases up to 15 August 2019 for meta‐analyses of observational studies and randomized controlled trials (RCTs) including low‐dose aspirin compared to placebo or other treatments. Based on random‐effects summary effect sizes, 95% prediction intervals, heterogeneity, small‐study effects and excess significance, signifi…

medicine.medical_specialtyPopulationLower riskPlacebo030226 pharmacology & pharmacySystematic Reviews and Meta‐analysisRisk Assessmentlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansPharmacology (medical)aspirin cancer cardiovascular disease meta-analysis umbrella review030212 general & internal medicineeducationPharmacologyAspirineducation.field_of_studyAspirinbusiness.industrytechnology industry and agriculturemedicine.diseaseMeta-analysisObservational studylipids (amino acids peptides and proteins)Upper gastrointestinal bleedingbusinessGastrointestinal Hemorrhagemedicine.drug
researchProduct

Magnesium and hypertension in old age

2021

Hypertension is a complex condition in which various actors and mechanisms combine, resulting in cardiovascular and cerebrovascular complications that today represent the most frequent causes of mortality, morbidity, disability, and health expenses worldwide. In the last decades, there has been an exceptional amount of experimental, epidemiological, and clinical studies confirming a close relationship between magnesium deficit and high blood pressure. Multiple mechanisms may help to explain the bulk of evidence supporting a protective effect of magnesium against hypertension and its complications. Hypertension increases sharply with advancing age, hence older persons are those most affected…

medicine.medical_specialtySettore MED/09 - Medicina InternaMagnesium supplementationchemistry.chemical_elementBlood Pressurelcsh:TX341-641Review030204 cardiovascular system & hematologyHypertension riskAging Cardiovascular disease03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseMagnesium deficiency (medicine)EpidemiologymedicineHumansMagnesium030212 general & internal medicineMicronutrientsIonIntensive care medicineAgedAged 80 and overNutrition and Dieteticsbusiness.industryMagnesiumagingInsulin resistanceFeeding Behaviormedicine.diseaseDietBlood pressurechemistryClose relationshipDietary SupplementsHypertensionionsbusinessMagnesium Deficiencylcsh:Nutrition. Foods and food supplyFood ScienceSupplement
researchProduct

ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiova…

2017

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

medicine.medical_specialtySettore MED/09 - Medicina InternaPCSK9 inhibitorMEDLINE030204 cardiovascular system & hematologyNOatherosclerosis; diagnostic and therapeutic pathways; hypercholesterolaemia; PCSK9 inhibitors; statins; sustainable health careDiagnostic and therapeutic pathways03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicine030212 general & internal medicineIntensive care medicineRisk managementCause of deathHypercholesterolaemiabusiness.industryAtherosclerotic cardiovascular diseaseCholesterolSustainable health careStatinsDiagnostic and therapeutic pathwayStatinHigh Cholesterol LevelsArticlesmedicine.diseaseAtherosclerosischemistryPCSK9 inhibitorsAtherosclerosiCardiologylipids (amino acids peptides and proteins)Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal Supplements : Journal of the European Society of Cardiology
researchProduct

Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observationa…

2018

The relevance of cardiovascular role played by levels of serum uric acid is dramatically growing, especially as cardiovascular risk factor potentially able to exert either a direct deleterious impact or a synergic effect with other cardiovascular risk factors. At the present time, it still remains undefined the threshold level of serum uric acid able to contribute to the cardiovascular risk. Indeed, the available epidemiological case studies are not homogeneous, and some preliminary data suggest that the so-called "cardiovascular threshold limit" may substantially differ from that identified as a cut-off able to trigger the acute gout attack. In such scenario, there is the necessity to clar…

medicine.medical_specialtySettore MED/09 - Medicina InternaPrognosiEpidemiologyPopulationDiseaseHyperuricemia030204 cardiovascular system & hematologyRisk AssessmentCardiovascular disease; Epidemiology; Uric acid; Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Italy; Prognosis; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Uric Acid; Internal Medicine; Cardiology and Cardiovascular Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRetrospective StudieRisk FactorsInternal medicineEpidemiologymedicineInternal MedicineHumansHyperuricemiaRisk factoreducationRetrospective Studies030203 arthritis & rheumatologyeducation.field_of_studybusiness.industryRisk FactorRetrospective cohort studyBiomarkermedicine.diseaseCardiovascular diseasePrognosisUric AcidchemistryItalyCardiovascular DiseasesResearch DesignUric acidCardiovascular disease; Epidemiology; Uric acidbusinessRisk assessmentCardiology and Cardiovascular MedicineBiomarkersHumanHigh blood pressurecardiovascular prevention : the official journal of the Italian Society of Hypertension
researchProduct

Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria

2017

The kidney is one of the major target organs of hypertension. Kidney damage represents a frequent event in the course of hypertension and arterial hypertension is one of the leading causes of end-stage renal disease (ESRD). ESRD has long been recognized as a strong predictor of cardiovascular (CV) morbidity and mortality. However, over the past 20 years a large and consistent body of evidence has been produced suggesting that CV risk progressively increases as the estimated glomerular filtration rate (eGFR) declines and is already significantly elevated even in the earliest stages of renal damage. Data was supported by the very large collaborative metaanalysis of the Chronic Kidney Disease …

medicine.medical_specialtySettore MED/09 - Medicina InternaRenal function030204 cardiovascular system & hematologyAsymptomatic03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicine030212 general & internal medicineSubclinical infectionSettore MED/14 - NefrologiaKidneyCreatinineProteinuriabusiness.industryArterial hypertension • Blood pressure • Glomerular filtration rate • Microalbuminuria • Proteinuria • Subclinical renal disease • Early kidney injury • Target organ damage • Cardiovascular disease • Cardiovascular risk assessmentmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureEndocrinologychemistryCardiologyMicroalbuminuriamedicine.symptombusinessKidney disease
researchProduct

Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study

2021

The Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension conceived and designed an ad hoc study aimed at searching for prognostic cut-off values of serum uric acid (SUA) in predicting combined (fatal and non-fatal) cerebrovascular (CBV) events in the whole database. The URic acid Right for heArt Health study is a nationwide, multicenter, observational cohort study involving data on subjects aged 18-95 years recruited on a regional community basis from all the territory of Italy under the patronage of the Italian Society of Hypertension with a mean follow-up period of 120.7 ± 61.8 months. A total of 14,588 subjects were included in the analysis. A prognos…

medicine.medical_specialtySettore MED/09 - Medicina Internauric acid cardiovascular riskserum uric acid; stroke; hypertension; cardiovascular prevention; cardiovascular diseasechemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansStrokeuric acid hypertensionbusiness.industryConfoundingPrognosismedicine.diseaseConfidence intervalUric AcidStrokechemistryHypertensionUric acidbusinessBody mass indexCohort studyKidney disease
researchProduct

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart diseas…

2013

AIMS: The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD).METHODS AND RESULTS: Of the theoretical estimated prevalence of 1/500 for heterozygous FH, <1% are diagnosed in most countries. Recently, direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals with FH, and up to 13-fold increased risk of CHD. Based on prev…

medicine.medical_specialtyStatinAtherosclerosis; Cardiovascular disease; Cholesterol; Coronary heart disease; Low-density lipoproteinSettore MED/09 - Medicina Internamedicine.drug_classPopulationCHILDRENFamilial hypercholesterolemiaBile acid bindingCOST-EFFECTIVENESS ANALYSIS030204 cardiovascular system & hematologyLDL-CHOLESTEROLDIAGNOSIS03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicineMANAGEMENT030212 general & internal medicineeducationHealth aging / healthy living Cardiovascular diseases [IGMD 5]Alirocumabeducation.field_of_studyCYTOKINE PATTERN CHANGEbusiness.industryLow-density lipoproteinmedicine.diseaseAtherosclerosisCardiovascular diseaseLomitapideDENSITY-LIPOPROTEIN APHERESIS3. Good healthASSOCIATION EXPERT PANELCoronary heart diseaseEndocrinologyCholesterolchemistryCARDIOVASCULAR-DISEASEAtherosclerosiCardiology and Cardiovascular MedicinebusinessSTATIN TREATMENTmedicine.drugEuropean Heart Journal
researchProduct